<?xml version="1.0" encoding="UTF-8"?>
<p id="p0345">and suppressing pro-inflammatory cytokines. MSC-based therapy might decrease the risk of CRS in COVID-19 patients by reducing the production of TNF-α, IFN-α, IL-1, IL-6, and IL-12 
 <xref rid="b0650" ref-type="bibr">[130]</xref>.
</p>
